Division of Experimental Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands; Department of Medicine, Unit of Cardiology, Karolinska Institute, and Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Molecular Cardiology, Department of Cardiology, Thoraxcenter; Cardiovascular Research School COEUR, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands;
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H299-309. doi: 10.1152/ajpheart.00578.2015. Epub 2016 May 27.
Uridine adenosine tetraphosphate (Up4A), a dinucleotide, exerts vascular influence via purinergic receptors (PR). We investigated the effects of Up4A on angiogenesis and the putative PR involved. Tubule formation assay was performed in a three-dimensional system, in which human endothelial cells were cocultured with pericytes with various Up4A concentrations for 5 days. Expression of PR subtypes and angiogenic factors was assessed in human endothelial cells with and without P2Y6R antagonist. No difference in initial tubule formation was detected between Up4A stimulation and control conditions at day 2 In contrast, a significant increase in vascular density in response to Up4A was observed at day 5 Up4A at an optimal concentration of 5 μM promoted total tubule length, number of tubules, and number of junctions, all of which were inhibited by the P2Y6R antagonist MRS2578. Higher concentrations of Up4A (10 μM) had no effects on angiogenesis parameters. Up4A increased mRNA level of P2YRs (P2Y2R, P2Y4R, and P2Y6R) but not P2XR (P2X4R and P2X7R) or P1R (A2AR and A2BR), while Up4A upregulated VEGFA and ANGPT1, but not VEGFR2, ANGPT2, Tie1, and Tie2. In addition, Up4A increased VEGFA protein levels. Transcriptional upregulation of P2YRs by Up4A was inhibited by MRS2578. In conclusion, Up4A is functionally capable of promoting tubule formation in an in vitro coculture system, which is likely mediated by pyrimidine-favored P2YRs but not P2XRs or P1Rs, and involves upregulation of angiogenic factors.
尿苷腺苷四磷酸 (Up4A) 是一种二核苷酸,通过嘌呤能受体 (PR) 发挥血管影响。我们研究了 Up4A 对血管生成和潜在的 PR 的影响。在三维系统中进行了小管形成测定,其中人内皮细胞与不同浓度的周细胞共培养 5 天。用和不用 P2Y6R 拮抗剂评估人内皮细胞中 PR 亚型和血管生成因子的表达。在第 2 天,与对照条件相比,Up4A 刺激没有检测到初始小管形成的差异。相反,在第 5 天,观察到对 Up4A 的血管密度显著增加。最佳浓度为 5μM 的 Up4A 促进总小管长度、小管数量和连接数量,所有这些都被 P2Y6R 拮抗剂 MRS2578 抑制。较高浓度的 Up4A(10μM)对血管生成参数没有影响。Up4A 增加了 P2YRs(P2Y2R、P2Y4R 和 P2Y6R)的 mRNA 水平,但不增加 P2XR(P2X4R 和 P2X7R)或 P1R(A2AR 和 A2BR),同时 Up4A 上调了 VEGFA 和 ANGPT1,但不上调 VEGFR2、ANGPT2、Tie1 和 Tie2。此外,Up4A 增加了 VEGFA 蛋白水平。Up4A 对 P2YRs 的转录上调被 MRS2578 抑制。总之,Up4A 在体外共培养系统中具有促进小管形成的功能,这可能是由嘧啶偏好的 P2YRs 介导的,但不是 P2XRs 或 P1Rs,涉及血管生成因子的上调。